Ryan Bushey
Digital Editor

Ryan Bushey is a digital editor for Advantage Business Media’s Science Group.  He covers scientific discoveries, emerging technologies and the business of the life sciences sector for R&D Magazine and Drug Discovery & Development along with managing social media for both publications. He’s an experienced journalist whose work has appeared in Business Insider, Slate, and Indiewire.

The tool works by measuring immune system biomarkers in blood samples and then uses machine learning algorithms to identify patterns in certain infections.
Digital Editor
|
9.19.2017
9:49am
Findings indicated one receptor was associated with successfully clearing a virus in experiments.
Digital Editor
|
9.18.2017
10:35am
Another pharmaceutical company revealed it would initiate a restructuring strategy designed to cut costs and streamline operations.
Digital Editor
|
9.13.2017
8:53am
A major pharmaceutical company may have an advantage in the competitive lung cancer treatment space. Details of their study were presented at the ESMO 2017...
Digital Editor
|
9.12.2017
8:46am
Data from this study was presented at the European Society for Medical Oncology taking place in Madrid, Spain.
Digital Editor
|
9.12.2017
8:46am
Advertisement
Overall, these total cuts come out to about 8 percent of Eli Lilly’s workforce.
Digital Editor
|
9.8.2017
8:58am
Investors who participated in this financing included existing investors like Medtronic and Boston Scientific.
Digital Editor
|
9.1.2017
8:00am
A team of scientists found a way to create a novel drug delivery system for an array of different conditions.
Digital Editor
|
8.31.2017
8:00am
Researchers presented results from a late stage study named COMPASS at the annual European Society of Cardiology Meeting taking place in Barcelona, Spain.
Digital Editor
|
8.28.2017
11:20am
E.coli carrying the mcr-1 and ndm-5 genes have made it immune to last-resort antibiotics.
Digital Editor
|
8.22.2017
11:25am
Findings from a previous phase IIa proof-of-concept trial indicated the compound is fast-acting and potent across multiple stages of the parasite’s lifecycle.
Digital Editor
|
8.21.2017
10:57am
This news is emblematic of how the development process can be a struggle for these next-gen cancer therapies.
Digital Editor
|
8.16.2017
11:20am
This breakthrough could help wipe the virus off the face of the earth.
Digital Editor
|
8.15.2017
10:09am
Advertisement
The drug is a potent and selective oral kappa opioid receptor being developed as an adjunctive treatment of major depressive disorder and substance use...
Digital Editor
|
8.15.2017
8:35am
Scientists at Arizona State University created the world’s first plant-based Zika vaccine that could be safer, more potent, and more cost-effective to produce...
Digital Editor
|
8.9.2017
10:42am
Investigators will randomize eligible participants into two treatment arms.
Digital Editor
|
8.9.2017
8:55am
Injections of exenatide showed signs of improving movement in Parkinson’s patients over a one year period.
Digital Editor
|
8.8.2017
2:12pm
The de-identified data that emerges from these tests will be analyzed for clues pertaining to how genetics and environmental factors combine to impact brain...
Digital Editor
|
8.4.2017
10:48am
Investigators tested the impact of 50 mg, 100 mg, or 200 mg against placebo on these patients.
Digital Editor
|
8.4.2017
9:58am
The Biden Cancer Initiative was spun off from the Biden Foundation in June 2017.
Digital Editor
|
8.2.2017
8:37am
Achieving these goals would give companies access to certain perks.
Digital Editor
|
8.1.2017
2:29pm
Advertisement
The company presented results from two studies involving potentially groundbreaking drugs.
Digital Editor
|
7.28.2017
9:37am
The firm completed a $42 million funding round aimed at advancing the company’s lead antibiotic candidate deeper into clinical development.
Digital Editor
|
7.27.2017
10:42am
A component of the common spice turmeric could be the key to killing treatment-resistant neuroblastoma tumor cells.
Digital Editor
|
7.26.2017
9:05am
The company’s clinical development program for this drug includes tests for over 30 tumor types in over 500 clinical trials.
Digital Editor
|
7.25.2017
10:43am
Proving this drug’s mechanism of action is viable could ultimately yield a multi-purpose therapy that could work for autoimmune conditions like lupus and...
Digital Editor
|
7.24.2017
1:37pm
Developing a potent therapy for Alzheimer’s disease will be one of the biggest healthcare challenges over the next few decades.
Digital Editor
|
7.21.2017
8:47am
The company's goal is to understand the link between infections, dysfunction of the gut’s enteric nervous system, and the early onset and chronic...
Digital Editor
|
7.20.2017
9:07am
The drugs are labeled VX-659, VX-152, and VX-440, respectively.
Digital Editor
|
7.19.2017
10:30am
This molecule serves as an integral multi-functioning ‘scaffolding’ protein vital to key functions of the brain.
Digital Editor
|
7.19.2017
10:10am
The 2017 International Society of Thrombosis and Hemostasis Congress was held July 8th through the 13th in Berlin, Germany.
Digital Editor
|
7.14.2017
10:32am
A breakthrough cancer treatment is one step closer to regulatory approval.
Digital Editor
|
7.13.2017
9:14am
Scientists have not been able to discern why this tissue becomes inflamed after trauma or infection until now.
Digital Editor
|
7.12.2017
9:43am
A division of the world’s largest food and drink company will launch a new startup focused on developing therapies for diseases associated with the microbiome.
Digital Editor
|
7.11.2017
10:36am
Implementing these new programs will fall under the framework of the 21st Century Cures Act.
Digital Editor
|
7.11.2017
8:54am
Cases of HF-PEF are expected to rise so this patient cohort could produce a lucrative opportunity for pharmaceutical companies.
Digital Editor
|
7.10.2017
11:08am
A new form of treatment for different types of cancer are showing signs of promise.
Digital Editor
|
7.7.2017
10:51am
The market for hemophilia treatments could see anemic growth over the next few years.
Digital Editor
|
7.6.2017
9:49am
Spinal muscular atrophy is a genetic condition characterized by loss of motor neurons in the spinal cord and lower brain stem inducing severe and progressive...
Digital Editor
|
7.5.2017
9:17am